leadf
logo-loader
viewHumanigen, Inc.

Humanigen bolsters partnership with Catalent to produce lenzilumab for coronavirus trials

Under the expanded partnership, Catalent will provide clinical supply support for Humanigen’s Phase 3 potential registration study of coronavirus (COVID-19) from its Philadelphia facility

Coronavirus graphic
The Mayo Clinic recently announced data on the first clinical use of lenzilumab in 12 patients with severe and critical Covid-19 pneumonia, the majority of whom showed rapid recovery and hospital discharge

Humanigen Inc (OTC:HGEN) and Catalent Biologics have expanded their partnership, which sees Catalent provide development, manufacturing and commercialization services for Humanigen’s drug lenzilumab, the companies announced Thursday. 

The Mayo Clinic recently announced data on the first clinical use of lenzilumab in 12 patients with severe and critical coronavirus (COVID-19) related pneumonia, the majority of whom showed rapid recovery and hospital discharge, the company said. A Phase 3 study is currently underway evaluating hospitalized coronavirus patients.

"Based on lenzilumab’s promising clinical data, we are pleased to expand our relationship with Catalent to solidify our ability to manufacture and supply lenzilumab," Humanigen CEO Cameron Durrant said in a statement. "If we are able to secure FDA approvals or Emergency Use Authorization, Catalent Biologics’ deep expertise and integrated OneBio solution will accelerate our ability to get this therapy to patients that need it most."

READ: Humanigen strengthens leadership team with three new executive appointments

Catalent Biologics has delivered early-stage development and clinical cGMP drug substance manufacturing for lenzilumab at its facility in Madison, Wisconsin. Under the expanded partnership, Catalent will also provide clinical supply support for Humanigen’s Phase 3 potential registration study of COVID-19 from its Philadelphia facility.

The company’s OneBio Suite is an integrated solution for the development, manufacturing and supply of biologic drugs. The suite of offerings is designed to accelerate timelines, reduce risk and simplify development.

“Catalent has partnered closely with Humanigen to develop and supply lenzilumab for clinical trials,” Catalent CCO Karen Flynn said. “The experience we already have with lenzilumab, and our OneBio integrated offering from development to supply, make Catalent uniquely suited to support Humanigen in the journey to make this promising therapy available to Covid-19 patients as soon as possible following receipt of regulatory approvals.”

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: Humanigen, Inc.

Price: - -

OTCMKTS:HGEN
Market: OTCQB
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Humanigen announces 71.8 million dollars in financing

Humanigen (OTCQB: HGEN) Chairman and CEO Cameron Durant joined Steve Darling from Proactive Vancouver with news the company has secured almost 72 million dollars in financing. Durant discusses those making up that financing which is a big part of the story..

on 3/6/20

2 min read